128 related articles for article (PubMed ID: 2962734)
1. CGS 16949A, a new nonsteroidal aromatase inhibitor: effects on hormone-dependent and -independent tumors in vivo.
Schieweck K; Bhatnagar AS; Matter A
Cancer Res; 1988 Feb; 48(4):834-8. PubMed ID: 2962734
[TBL] [Abstract][Full Text] [Related]
2. Antitumor effects of a nonsteroidal aromatase inhibitor (CGS 16949A) on 7, 12-dimethylbenz[alpha]anthracene-induced mammary tumors in rats.
Iino Y; Sugamata N; Owada S; Tago T; Sato H; Yokoe T; Maemura M; Morishita Y; Horiuchi R
Jpn J Clin Oncol; 1991 Jun; 21(3):153-9. PubMed ID: 1834875
[TBL] [Abstract][Full Text] [Related]
3. Antiproliferative effect of the new aromatase inhibitor fadrozole on pre- and postmenopausal models of rat mammary tumor.
Tanaka M; Yano S; Hasegawa Y; Nakao K
Arzneimittelforschung; 1994 Jun; 44(6):774-8. PubMed ID: 8053980
[TBL] [Abstract][Full Text] [Related]
4. Antitumor and endocrine effects of an aromatase inhibitor (CGS 16949A) on DMBA-induced rat mammary tumor.
Houjou T; Wada T; Yasutomi M
Clin Ther; 1993; 15(1):137-47. PubMed ID: 8458043
[TBL] [Abstract][Full Text] [Related]
5. Antitumor effects of SEF19, a new nonsteroidal aromatase inhibitor, on 7,12-dimethylbenz[a]anthracene-induced mammary tumors in rats.
Iino Y; Karakida T; Sugamata N; Andoh T; Takei H; Takahashi M; Yaguchi S; Matsuno T; Takehara M; Sakato M; Kawashima S; Morishita Y
Anticancer Res; 1998; 18(1A):171-6. PubMed ID: 9568073
[TBL] [Abstract][Full Text] [Related]
6. Preliminary study of the treatment of advanced breast cancer in postmenopausal women with the aromatase inhibitor CGS 16949A.
Stein RC; Dowsett M; Davenport J; Hedley A; Ford HT; Gazet JC; Coombes RC
Cancer Res; 1990 Mar; 50(5):1381-4. PubMed ID: 2137367
[TBL] [Abstract][Full Text] [Related]
7. Antitumoral and endocrine effects of (+)-vorozole in rats bearing dimethylbenzanthracene-induced mammary tumors.
De Coster R; Van Ginckel RF; Callens MJ; Goeminne NK; Janssens BL
Cancer Res; 1992 Mar; 52(5):1240-4. PubMed ID: 1737385
[TBL] [Abstract][Full Text] [Related]
8. Antitumor effect of a specific aromatase inhibitor, 1-methyl-androsta-1,4-diene-3,17-dione (atamestane), in female rats bearing DMBA-induced mammary tumors.
Nishino Y; Schneider MR; Michna H; el Etreby MF
J Steroid Biochem; 1989; 34(1-6):435-7. PubMed ID: 2533949
[TBL] [Abstract][Full Text] [Related]
9. Effect of CGS 16949A plus tamoxifen on induced mammary tumours in rats.
Tominaga T; Yoshida Y; Shimozuma K; Hayashi K; Kosaki G
Eur J Cancer; 1990; 26(5):600-3. PubMed ID: 2144748
[TBL] [Abstract][Full Text] [Related]
10. The new aromatase inhibitor CGS-16949A suppresses aldosterone and cortisol production by human adrenal cells in vitro.
Lamberts SW; Bruining HA; Marzouk H; Zuiderwijk J; Uitterlinden P; Blijd JJ; Hackeng WH; De Jong FH
J Clin Endocrinol Metab; 1989 Oct; 69(4):896-901. PubMed ID: 2550511
[TBL] [Abstract][Full Text] [Related]
11. Specificity of low dose fadrozole hydrochloride (CGS 16949A) as an aromatase inhibitor.
Santen RJ; Demers LM; Lynch J; Harvey H; Lipton A; Mulagha M; Hanagan J; Garber JE; Henderson IC; Navari RM
J Clin Endocrinol Metab; 1991 Jul; 73(1):99-106. PubMed ID: 1646219
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of aromatase with CGS 16949A in postmenopausal women.
Santen RJ; Demers LM; Adlercreutz H; Harvey H; Santner S; Sanders S; Lipton A
J Clin Endocrinol Metab; 1989 Jan; 68(1):99-106. PubMed ID: 2521224
[TBL] [Abstract][Full Text] [Related]
13. Novel aromatase inhibitors.
Bhatnagar AS; Häusler A; Schieweck K; Browne LJ; Bowman R; Steele RE
J Steroid Biochem Mol Biol; 1990 Nov; 37(3):363-7. PubMed ID: 2147860
[TBL] [Abstract][Full Text] [Related]
14. A phase I trial of CGS 16949A. A new aromatase inhibitor.
Lipton A; Harvey HA; Demers LM; Hanagan JR; Mulagha MT; Kochak GM; Fitzsimmons S; Sanders SI; Santen RJ
Cancer; 1990 Mar; 65(6):1279-85. PubMed ID: 2137721
[TBL] [Abstract][Full Text] [Related]
15. Effect of aromatase inhibitors on growth of mammary tumors in a nude mouse model.
Yue W; Wang J; Savinov A; Brodie A
Cancer Res; 1995 Jul; 55(14):3073-7. PubMed ID: 7606729
[TBL] [Abstract][Full Text] [Related]
16. Antitumor effect of pyridoglutethimide, an aromatase inhibitor, on 7,12-dimethylbenz(a)anthracene-induced mammary tumors of rat.
Yamamoto T; Urabe M; Tamura T; Kitawaki J; Honjo H; Okada H
Anticancer Res; 1991; 11(6):1999-2002. PubMed ID: 1776832
[TBL] [Abstract][Full Text] [Related]
17. Effects of aromatase inhibitor 4-hydroxyandrostenedione and other compounds in the 7, 12-dimethylbenz(a)anthracene-induced breast carcinoma model.
Brodie AM; Garrett WM; Hendrickson JR; Tsai-Morris CH
Cancer Res; 1982 Aug; 42(8 Suppl):3360s-3364s. PubMed ID: 6805949
[TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo studies demonstrating potent and selective estrogen inhibition with the nonsteroidal aromatase inhibitor CGS 16949A.
Steele RE; Mellor LB; Sawyer WK; Wasvary JM; Browne LJ
Steroids; 1987; 50(1-3):147-61. PubMed ID: 2973160
[TBL] [Abstract][Full Text] [Related]
19. Highly selective inhibition of estrogen biosynthesis by CGS 20267, a new non-steroidal aromatase inhibitor.
Bhatnagar AS; Häusler A; Schieweck K; Lang M; Bowman R
J Steroid Biochem Mol Biol; 1990 Dec; 37(6):1021-7. PubMed ID: 2149502
[TBL] [Abstract][Full Text] [Related]
20. Effects of aromatase inhibitors, aminoglutethimide, and 4-hydroxyandrostenedione on cyclic rats and rats with 7,12-dimethylbenz(a)anthracene-induced mammary tumors.
Wing LY; Garrett WM; Brodie AM
Cancer Res; 1985 Jun; 45(6):2425-8. PubMed ID: 3921242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
